Clinical Trials Logo

Chemotherapy clinical trials

View clinical trials related to Chemotherapy.

Filter by:

NCT ID: NCT05969158 Not yet recruiting - Clinical trials for Chemotherapy-Induced Thrombocytopenia

Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma

Start date: September 4, 2023
Phase: Phase 2
Study type: Interventional

To explore the efficacy and safety of hetrombopag for secondary prevention of thrombocytopenia caused by XPO-1 inhibitor Selinexor combined with chemotherapy in patients with lymphoma.

NCT ID: NCT05966441 Not yet recruiting - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Role of Curcumin in Paclitaxel Induced PN

Start date: August 30, 2023
Phase: Phase 2
Study type: Interventional

Paclitaxel induced peripheral neuropathy is the most common and serious side effect associated with Paclitaxel treatment in breast cancer patients receiving Paclitaxel. The efficacy of antioxidant molecules as neuroprotective strategies to preventing the development of peripheral neuropathy has been investigated in preclinical and clinical studies. Vitamin E and Glutathione have been explored as adjuvant therapies to preventing taxane-induced peripheral neuropathy. Other tested neuroprotective treatments with limited success include amifostine, glutamine and acetyl l-carnitine. Curcumin's antioxidant capacity is similar to other potent antioxidants, such as trolox (a vitamin E analog). Curcumin inhibits lipid peroxidation in different tissues, regulates intracellular levels of antioxidant enzymes (e.g., catalase, glutathione peroxidase and superoxide dismutase) and is an effective intracellular reactive oxygen species (ROS) scavenger. The investigators are going to investigate the neuroprotective effect of Curcumin against Paclitaxel induced peripheral neuropathy.

NCT ID: NCT05944211 Not yet recruiting - Clinical trials for Chemotherapy-Induced Thrombocytopenia

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia

H-CIT-AML
Start date: July 2023
Phase: Phase 2
Study type: Interventional

Randomized, controlled, open study to evaluate the efficacy and safety of Hetrombopag in the treatment of chemotherapy-induced thrombocytopenia(CIT) in patients with acute myeloid leukemia

NCT ID: NCT05941741 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Start date: January 10, 2024
Phase: Phase 3
Study type: Interventional

This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.

NCT ID: NCT05941598 Not yet recruiting - Clinical trials for Chemotherapy-Related Cognitive Impairment

Electroacupuncture for Chemotherapy-Related Cognitive Impairment

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

The objective of this trial is to evaluate the effect of electroacupuncture compared to sham acupuncture in preventing CRCI among breast cancer patients scheduled to undergo chemotherapy.

NCT ID: NCT05935956 Recruiting - Neuropathic Pain Clinical Trials

Safety and Effectiveness of Magnetic Peripheral Nerve Stimulation for the Treatment of Chemotherapy Induced Neuropathy

mPNS-CH
Start date: June 9, 2023
Phase:
Study type: Observational

Assess the safety and effectiveness of Axon Therapy in the treatment of chemotherapy-induced neuropathy

NCT ID: NCT05927857 Not yet recruiting - Chemotherapy Clinical Trials

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

Start date: September 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Primary Objectives - In phase 1b cohort, to determine MTD (maximum tolerated dose) of nal-IRI (ONIVYDE®) in combination with Ramucirumab (Cyramza®) and TAS-102 (LONSURF®) - In phase II cohort, to evaluate disease objective response rate (ORR) of Ramucirumab (Cyramza®), nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®) Secondary Objectives - To evaluate disease control rate (DCR) - To evaluate progression-free survival (PFS) - To evaluate overall survival (OS) - To assess the safety profile - To study the blood biomarkers

NCT ID: NCT05909813 Completed - Breast Cancer Clinical Trials

Individualized Piano Instruction (IPI) for Improving Cognition in Breast Cancer Survivors.

Start date: January 8, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to test the study method and procedure for individualized piano instruction (IPI) and its impact on chemotherapy related cognitive impairment (CRCI) symptoms. There have been studies that show the benefits of leaning to play the piano keyboard on cognitive skills in children and elderly populations. The information collected from the program will be used to examine the feasibility of implementing this program permanently

NCT ID: NCT05904340 Not yet recruiting - Breast Neoplasms Clinical Trials

Transcutaneous Electrical Acupoint Stimulation on Symptoms Associated With Chemotherapy Induced Peripheral Neuropathy

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

Breast cancer ranks first in Taiwan's top ten gynecological cancers. Chemotherapy is a standard treatment method for colorectal cancer and breast cancer, but while destroying cancer cells, it also destroys healthy cells, resulting in side effects. Peripheral neuropathy can lead to peripheral nerve damage and decreased activity, which affects the patient's quality of life. Currently, there is no standard and effective method for treating peripheral neuropathy caused by chemotherapy. Therefore, the purpose of this study is to investigate the effect of percutaneous electrical acupoint stimulation on improving peripheral nerve symptoms in breast cancer patients undergoing chemotherapy.

NCT ID: NCT05885126 Enrolling by invitation - Nursing Caries Clinical Trials

The Effect of Mandala Technique on Acute Nausea-vomiting and Comfort Level in Cancer Patients

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

Cancer is an important health problem in the world and in our country, and it ranks second among the causes of death in our country (20.7%). Chemotherapy, one of the most commonly used methods in cancer treatment, causes many physical and emotional symptoms while treating the disease. Nausea-vomiting is a common problem in cancer care, especially in patients receiving chemotherapy. In the literature, there are studies examining non-pharmacological interventions for the prevention and management of nausea and vomiting in patients receiving chemotherapy, and it is seen that the interventions are mostly within the scope of complementary and alternative approaches. Patients receiving ambulatory chemotherapy may experience anticipatory nausea in particular, and this is likely to affect the individual's comfort level. In studies conducted in the field, the comfort level of cancer patients receiving chemotherapy was determined as moderate. Today, mandalas are used effectively in the field of art therapy. The possibility of using mandala in all age groups has contributed to the treatment process of different diseases and disorders, and its effectiveness has been presented to the scientific world with many researches around the world. In adults, the mandala has been used both in the treatment of psychiatric disorders and as a tool to observe the effects of treatments. Art therapy including mandala drawing has significantly reduced the severity of trauma symptoms in individuals with anxiety disorders and post-traumatic stress disorder. In the study of Zhao & Tang (2017) it was determined that mandala drawing therapy reduced the anxiety of cancer patients. If the reduction of nausea-vomiting affects the comfort level and the person is relieved, a more effective treatment environment is created and the quality of life of the person is increased. In the literature, very limited studies have been reached on the use of the mandala drawing technique in cancer patients. National and international research examining the mandala drawing technique, especially in patients receiving ambulatory chemotherapy, could not be reached. The aim of this study is to determine the effect of mandala drawing technique on nausea-vomiting and comfort level in patients receiving ambulatory chemotherapy. It is anticipated that the study to be conducted will contribute to nursing interventions in the cancer care process and lead to the planning of new research on the subject.